Interim report January-March 2008

Strong sales and income growth

• Sales increased by 19 percent to SEK 58.7 (49.2) million. Calculated in local sales currencies growth was 20 percent.

• Gross income increased by 20 percent to SEK 40.5 (33.8) million, the gross margin was 69 percent (69).

• Operating income increased by 33 percent and amounted to SEK 10.6 (8.0) million, which gives an operating margin of 18 (16) percent.

• Operating income before research and development costs increased by 25 percent to SEK 18.3 (14.6) million. This corresponds to a margin of 31 (30) percent.

• Consolidated net income was SEK 8.1 (11.0) million, which gives earnings per share of SEK 0.41 (0.55). However, last year’s figure includes capitalization of the deferred tax asset in loss carry-forward for tax purposes to the tune of SEK 4.1 million. Adjusted for this item net income increased by 18 percent.

• The cash flow from operating activities amounted to SEK 6.7 (5.0) million, an increase of 34 percent.

• The equity/assets ratio amounted to 84 percent (82).

• Acquisition of majority shareholding in Italian distributor.

• Start of direct marketing of all fertility products in France announced.

• Products for the cold storage of embryos approved in Canada and in Europe.

• IVF products approved in Russia.


April 28, 2008
Kungsbacka, Sweden

Magnus Nilsson
CEO


Queries should be addressed to:
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

---